11月8日,治疗阿尔茨海默病的生物技术公司木薯科学(SAVA)股价在盘中飙升6.76%。这一异动引起了市场广泛关注,投资者对公司新药研发进展抱有较高预期。
最新资料显示,木薯科学目前正在开展两项关键的III期临床试验,分别测试其研发的新药simufilam用于治疗阿尔茨海默病的安全性和疗效。作为新一代治疗阿尔茨海默病的药物,simufilam若能最终获批上市,必将为阿尔茨海默病患者带来福音。
除simufilam外,木薯科学还研发了另一项名为SavaDx的诊断技术,旨在提早发现阿尔茨海默病的存在。该技术可通过简单的血液检测,数年前就发现病症。如果诊断技术能够同步获批,或将为早期发现疾病、采取干预措施带来便利。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.